Jeffrey Poulton Sells 2,242 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Jeffrey Poulton sold 2,242 shares of the firm’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the transaction, the executive vice president directly owned 59,802 shares of the company’s stock, valued at approximately $18,543,404.16. This represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Alnylam Pharmaceuticals Stock Up 5.8%

Shares of NASDAQ ALNY traded up $18.21 during mid-day trading on Tuesday, reaching $332.61. 1,516,365 shares of the company’s stock traded hands, compared to its average volume of 1,632,567. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The stock has a market cap of $44.11 billion, a P/E ratio of 194.51 and a beta of 0.35. The business has a 50-day simple moving average of $372.67 and a 200 day simple moving average of $424.73. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The business had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s revenue was up 84.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.65) EPS. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ALNY. Root Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. HM Payson & Co. acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $27,000. Finally, Ameriflex Group Inc. bought a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $32,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Piper Sandler restated an “overweight” rating and issued a $489.00 price target (up from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Morgan Stanley lowered their price target on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a report on Friday, January 30th. Finally, Oppenheimer started coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective for the company. Twenty-two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.